Summary
Unable to evaluate most claims: the prompt provides only limited KEVZARA label excerpts (Sections 5.1, 2.1, 2.6, 6.1, 17) that address mainly serious infections/holding/avoid active infection. All other claims (indication, dosing, trial efficacy, MTX/other DMARD combinations, dose reduction criteria, vaccine/lab monitoring specifics, drug interactions, other JAK inhibitors) are not supported or contradicted by the supplied excerpts, so they cannot be verified against the official label text provided.
Category Scores
Accurate Statements
Kevzara should be avoided in active infections.
Supported by Section 5.1 and 2.1: “Avoid use of KEVZARA in patients with an active infection… Evaluate for infections: Avoid KEVZARA use in patients with active infections.”
Kevzara should be discontinued/held if a serious infection or opportunistic infection occurs.
Supported by Section 5.1 and 2.6: “Hold treatment with KEVZARA if a patient develops a serious infection or an opportunistic infection.”
Kevzara may lower resistance to infections and patients should contact their physician when infection symptoms appear.
Supported by Section 17 Patient Counseling: “KEVZARA may lower their resistance to infections… contact their physician immediately when symptoms suggesting infection appear.”
Unsupported Statements
Kevzara (sarilumab) is approved for moderate to severe rheumatoid arthritis (RA) in adults who have not responded well to one or more tumor necrosis factor (TNF) antagonists.
Not supported by the provided label excerpts (only serious infections/avoid active infection/holding guidance are included).
Kevzara can be used alongside methotrexate (MTX).
Not supported or contradicted by the provided excerpts.
In the MOBILITY trial, patients on stable MTX received Kevzara 200 mg or 150 mg subcutaneously every two weeks.
Not supported by the provided excerpts.
In the MOBILITY trial, Kevzara plus MTX showed significant improvements in signs and symptoms of RA compared to placebo.
Not supported by the provided excerpts.
In the MOBILITY trial, ACR20 response rates were 61% with Kevzara 200 mg plus MTX and 55% with Kevzara 150 mg plus MTX, compared with 36% with placebo plus MTX.
Not supported by the provided excerpts.
TARGET (TNF-inadequate responders) demonstrated similar benefits for Kevzara plus MTX versus placebo plus MTX.
Not supported by the provided excerpts.
TARGET demonstrated additive effects without MTX withdrawal.
Not supported by the provided excerpts.
The recommended starting dose of Kevzara is 200 mg every two weeks.
Dose recommendations are not provided in the supplied excerpts.
The Kevzara dose may be reduced to 150 mg if needed for lab abnormalities or tolerability.
Dose modification details (beyond holding for serious infection/opportunistic infection) are not included in the supplied excerpts.
No dose adjustments for MTX are required when combined with Kevzara.
Not addressed in the supplied excerpts.
When Kevzara is combined with MTX, liver enzymes, blood counts, and lipids should be monitored closely due to increased hepatotoxicity risk.
Monitoring for liver enzymes/blood counts/lipids and hepatotoxicity risk are not described in the supplied excerpts.
Combining Kevzara with MTX increases infection risk, including upper respiratory infections and herpes zoster.
The supplied excerpts discuss serious/opportunistic infections and avoidance/holding, but do not mention URIs or herpes zoster specifically.
Combining Kevzara with MTX can cause lab issues such as neutropenia or elevated ALT/AST.
The supplied excerpts do not mention neutropenia or ALT/AST.
Kevzara should be discontinued if severe issues arise (as stated in the provided text).
The supplied excerpts only explicitly support holding treatment for serious/opportunistic infection; they do not establish broad ‘discontinue for severe issues’ language.
Kevzara should be avoided with live vaccines.
Not present in the supplied excerpts.
Kevzara should be skipped if MTX intolerance, liver disease, or cytopenias exist.
Not present in the supplied excerpts (the excerpted 2.6 text mentions dosage modifications for cytopenias/abnormal liver enzymes/infections only in heading but the actual provided content includes infection/holding guidance only).
For elderly patients or those with renal impairment, lower MTX doses may be needed independently.
Not addressed in the supplied excerpts.
No Kevzara-specific interactions beyond general immunosuppressant overlap were noted in the provided text.
Not supported by the supplied excerpts.
Switching to Kevzara monotherapy (instead of combining with MTX) is described as less effective per trials in the provided text.
Not supported by the supplied excerpts.
Kevzara can be paired with other DMARDs like leflunomide.
Not supported by the supplied excerpts.
Olumiant (baricitinib) can be combined with MTX.
Not related to the supplied KEVZARA label excerpts and not supportable from them.
Rinvoq (upadacitinib) can be combined with MTX.
Not related to the supplied KEVZARA label excerpts and not supportable from them.
Contradictions
Important Omissions
Most claims cannot be verified against the official label because only infection/holding excerpts (5.1, 2.1, 2.6 infection-related holding, 6.1 infection experience, 17 counseling) were provided. Label sections for indications, dosing, dose modifications (non-infection), contraindications, vaccines, lab monitoring details, drug interactions, and MTX/DMARD combination guidance are not included.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
Several safety-relevant claims (e.g., detailed lab monitoring, vaccine avoidance, dosing modifications, infection-risk specifics) are not supported by the supplied label excerpts; therefore, an on-label adherence determination for those statements cannot be made from the provided prescribing information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Insufficient label evidence provided to verify most AI claims; only infection/holding/avoid active infection content can be assessed from the excerpts.
Suggested Improvement
Provide the full KEVZARA label sections for indication/dosing/dose modifications/contraindications/warnings-precautions (including vaccines, lab monitoring), drug interactions, and combination therapy statements; then re-audit each claim against those exact sections.